Using AD transgenic mice as well as human neuroblastoma SH-SY5Y cells, they determined that VPA inhibited both the activities of GSK3β and CDK5 kinases, and consequently reduced Tau hyperphosphorylation. The gene discussed is MAPT; the disease is Alzheimer disease.